Atour Lifestyle Holdings combines asset-light franchising with high-margin lifestyle retail, driving strong growth in China’s hotel market. Its franchised network delivers high returns on invested capital and robust free cash flow, supported by an 80%+ direct booking rate through its large A-CARD ecosystem. Retail revenue surged 67% year-over-year to RMB 3.67 billion in FY2025, now nearly 40% of total revenue, boosting margins. The company maintains a net cash position, pays regular dividends, and leads China’s upper-midscale hotel segment with expansion potential in lower-tier cities.
Atour Lifestyle Holdings is the subject of this story. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Sep 17, 2026 17:11 WIB: Out of 105 priced US stocks, 85 rose and 15 fell today. Notable movers include Allbirds Inc (BIRD) at USD 2.31 with a 1-day change of -2.53%, Firy Inc. (FIRY) at USD 10.04 down 2.52%, and Tapestry, Inc. (TPR) at USD 120.16 up 1.88%.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
